NUS Links:
Multiple myeloma (MM) is a type of blood cancer that originates from abnormal plasma cells in the bone marrow, leading to serious complications such as bone damage, anaemia, kidney dysfunction,
Multiple primary cancers (MPC) often indicate a hereditary cancer predisposition syndrome. In a study led by Prof Lee Soo Chin, 19% of 3514 cancer patients who underwent germline genetic testing
Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow, leading to the buildup of abnormal lymphocytes. It is the most common form of
Muscle is our first line of defence against cancer. A randomised clinical trial in Singapore, led by N2CR members A/Prof Alfredo Franco-Obregon & Dr Alex Tai Yee Kit, with N2CR
Nasopharyngeal carcinoma (NPC) is common in South China and parts of Southeast Asia. Despite treatment, 20-30% of patients relapse within five years and ultimately become resistant to standard platinum-based chemotherapy;
A study led by Dr Alan Prem Kumar, a member of N2CR, delves into how cancer arises from disruptions in cell cycle regulation, driven by mutations that fuel unchecked division
Gastric cancer (GC) has significant global mortality with high heterogeneity. A study of 226 GC samples from 121 patients integrated spatial transcriptomics and single-cell expression profiles, revealing extensive intratumour heterogeneity
The tumour microenvironment (TME) plays a pivotal role in cancer progression, metastasis, and therapeutic resistance. Comprised of diverse cells, extracellular matrix, and signaling molecules, the TME drives processes like epithelial-mesenchymal
Research led by N2CR member Dr. Cheok Chit Fang found that the tumour suppressor protein p53 protects DNA during replication by preventing the hyperactivation of PARP1 caused by oxidative stress.
Gold nanoparticles (NPs) are promising for cancer therapy due to their versatile properties. However, their interactions with cells vary, affecting reproducibility and application. To optimise this, Dr Andy Tay Kah